ENTITY
Glenmark Pharmaceuticals

Glenmark Pharmaceuticals (GNP IN)

183
Analysis
Health Care • India
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company that develops, manufactures, and markets branded and generic formulations, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company focuses on therapeutic areas including respiratory, dermatology, and oncology, with products such as Ryaltris, Winlevi, and Candid. It was founded in 1977 and is headquartered in Mumbai, India.
more
•04 Nov 2019 15:51

Asia HY Monthly - Corporate Governance And Corruption In Indonesia - Lucror Analytics

In this month’s “In-Focus” section, we provide an update on recent events in Indonesia that we believe will have an impact on offshore investor...

Logo
533 Views
Share
•24 Oct 2019 16:00

Asia HY Trade Recommendations - October 2019 - Lucror Analytics

The Asia HY Trade Recommendations report for October includes a summary of our recommendations, as well as our high-conviction ideas. We also...

Logo
519 Views
Share
•08 Oct 2019 00:00

Lucror Analytics - Morning Views Asia - 08 Oct 2019

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region,...

Logo
109 Views
Share
•02 Oct 2019 00:00

Asia HY Monthly - Macau Gaming Update - Lucror Analytics

In this month’s In-Focus, we provide an update on the Macau gaming sector, including our market outlook, concession renewals and a peer...

Logo
218 Views
Share
•27 Sep 2019 00:00

Glenmark - Tear Sheet - Lucror Analytics

We view Glenmark Pharmaceuticals as “Medium Risk” on the LARA scale. Our opinion is primarily based on the company’s sound track record of...

Logo
172 Views
Share
x